Roberta Zangaglia
Overview
Explore the profile of Roberta Zangaglia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitrotti P, Vegezzi E, Zangaglia R, Palmieri I, Dicaire M, Gana S, et al.
Neurol Genet
. 2024 Nov;
10(6):e200208.
PMID: 39512794
Objectives: To report a novel imaging finding of bilateral dentate nuclei hyperintensities in a case of childhood-onset GAA--related ataxia (spinocerebellar ataxia 27B, SCA27B) and response to 4-aminopyridine (4-AP). Methods: A...
2.
Pocora M, Avenali M, Croce M, Ferrari F, Valentino F, Pacchetti C, et al.
Mov Disord Clin Pract
. 2024 Sep;
12(1):115-117.
PMID: 39329221
No abstract available.
3.
Regalbuto S, Zangaglia R, Valentino F, Todisco M, Pacchetti C, Ramusino M, et al.
Eur J Neurol
. 2024 Aug;
31(12):e16448.
PMID: 39207116
Background And Purpose: The pathogenesis of idiopathic normal pressure hydrocephalus (iNPH) remains controversial. Limited studies have indicated a high prevalence of obstructive sleep apnoea (OSA) amongst iNPH patients. The aim...
4.
Avenali M, Zangaglia R, Cuconato G, Palmieri I, Albanese A, Artusi C, et al.
J Neurol Neurosurg Psychiatry
. 2023 Oct;
95(4):309-315.
PMID: 37879897
Background: variants increase the risk of developing Parkinson disease (PD) and influence its outcome. Deep brain stimulation (DBS) is a recognised therapeutic option for advanced PD. Data on DBS long-term...
5.
Cilia R, Cereda E, Piatti M, Pilotto A, Magistrelli L, Andreasi N, et al.
Mov Disord Clin Pract
. 2023 Apr;
10(4):625-635.
PMID: 37070060
Background: Effects of dopaminergic medications used to treat Parkinson's disease (PD) may be compared with each other by using conversion factors, calculated as Levodopa equivalent dose (LED). However, current LED...
6.
Lancione M, Cencini M, Costagli M, Donatelli G, Tosetti M, Giannini G, et al.
Neuroimage Clin
. 2022 Mar;
34:102989.
PMID: 35303599
The non-invasive quantification of iron stores via Quantitative Susceptibility Mapping (QSM) could play an important role in the diagnosis and the differential diagnosis of atypical Parkinsonisms. However, the susceptibility (χ)...
7.
Sproviero D, Gagliardi S, Zucca S, Arigoni M, Giannini M, Garofalo M, et al.
Front Aging Neurosci
. 2022 Mar;
14:785741.
PMID: 35250537
Objectives: There is a lack of effective biomarkers for neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia. Extracellular vesicle (EV)...
8.
Rey F, Pandini C, Messa L, Launi R, Barzaghini B, Zangaglia R, et al.
Aging Cell
. 2021 Nov;
20(12):e13504.
PMID: 34799977
SNCA protein product, α-synuclein, is widely renowned for its role in synaptogenesis and implication in both aging and Parkinson's disease (PD), but research efforts are still needed to elucidate its...
9.
Schindler A, Pizzorni N, Cereda E, Cosentino G, Avenali M, Montomoli C, et al.
J Neurol Sci
. 2021 Oct;
430:120008.
PMID: 34624796
Background: Dysphagia is common in Parkinson's disease (PD). The effects of antiparkinsonian drugs on dysphagia are controversial. Several treatments for dysphagia are available but there is no consensus on their...
10.
Cosentino G, Avenali M, Schindler A, Pizzorni N, Montomoli C, Abbruzzese G, et al.
J Neurol
. 2021 Aug;
269(3):1335-1352.
PMID: 34417870
Background: Parkinson's disease (PD) is a neurodegenerative disorder characterized by a combination of motor and non-motor dysfunction. Dysphagia is a common symptom in PD, though it is still too frequently...